Collection of Venous and Capillary Blood Samples Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)
Cobas® Lumira 静脉和毛细血管血样采集用于新型诊断设备的研究、优化和校准 (EVOLVE)
This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira instrument. This instrument is a diagnostic medical device with single-use test strips, that allows diagnostic testing right at the patient's side. The aim is to improve doctors' ability to monitor health conditions more quickly and easily.
Approximately 30,000 patients are expected to participate in this study, across multiple UK sites.
研究概览
地位
详细说明
This prospective, multicenter sample collection study will involve the collection of venous and capillary blood samples from approximately 12,000 participants across the 8 study cohorts A-H. The EVOLVE study will be conducted at study sites in the United Kingdom (UK). Collected samples may be tested at the study sites and at the in-house laboratory at LumiraDx UK Ltd (hereafter referred to as 'LumiraDx UK'. LumiraDx UK is a member of the Roche Group.) on the cobas® lumira platform using the cobas® lumira Test Strip.
Venous samples also will be sent to LumiraDx UK and/or Roche Germany for testing on a reference method. Participants presenting to medical units (including but not limited to A&E departments, hospital ward, or outpatient clinics) with signs and symptoms of diseases related to but not limited to embolism, infection, inflammation, cardiovascular, renal conditions, metabolic disorders, oral anticoagulant therapy, hypercholesterolemia, and hepatic disorder will be enrolled. Participants will be assigned to a study cohort based on primary presenting condition at the time of enrollment.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Zoe Pounce, PhD
- 电话号码:+44 1786 533 206
- 邮箱:zoe.pounce@roche.com
学习地点
-
-
-
Glasgow、英国、G81 4HX
- 招聘中
- Golden Jubilee National Hospital
-
接触:
- Research Office
- 电话号码:+44141 951 5000
- 邮箱:gjnh.projects@gjnh.scot.nhs.uk
-
首席研究员:
- Roy Gardner, MBChB MD MRCP FESC FHFA FACC
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
UK-based adults presenting to a study site and meeting the eligibility criteria. There are no demographic requirements for this study
描述
Inclusion Criteria:
-
Willing and able to provide written informed consent.
-
Willing to comply with study procedures.
-
The participant must present as one of the following cohorts (primary presenting condition):
- Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)
- Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)
- Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)
- Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)
- Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)
- Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)
- Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )
- Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).
Inclusion Criteria for Cohorts A, B, C, D, E, G, and H:
1. Participants ≥ 18 years of age
Inclusion Criteria for Cohort F (Diabetes Cohort):
1. Participants ≥ 16 years old
Exclusion Criteria:
- Subjects deemed inappropriate for the study by the Principal Investigator.
- Participants who have previously been enrolled in the EVOLVE study in the past 60 days.
Exclusion Criteria for Cohort E (Oral Anticoagulation Cohort):
- Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.
- Subjects who have anti-phospholipid antibody syndrome (APS)
- The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:CROSS_SECTIONAL
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Blood clot
participants presenting with symptoms indicative of thromboembolic events |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
Infection/Inflammation
participants presenting with symptoms indicative of infection or inflammatory disorders |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
Heart disease
participants presenting with symptoms indicative of heart failure or acute coronary syndrome |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
Kidney disease
participants presenting with symptoms indicative of renal disorders |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
Blood thinners
participants with ongoing vitamin K antagonist therapy for at least four weeks |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
Diabetes
participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2 |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
High cholesterol
participants presenting with symptoms indicative of Hypercholesterolemia |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
|
Liver disease
participants with symptoms indicative of hepatic disorders |
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biomarker concentration
大体时间:Baseline
|
Blood samples will be used to take a quantitative baseline measurement of 1 or more biomarkers associated with the following health conditions:
Measurements are used for research, development and calibration of point-of-care diagnostic tests, and may compare results between different test methods. There is no statistical analysis planned on these measurements. |
Baseline
|
合作者和调查者
调查人员
- 首席研究员:Roy S Gardner, MBChB, MD、Golden Jubilee National Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- RD007454
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.